Sustained Endocytosis Inhibition via Locally‐Injected Drug‐Eluting Hydrogel Improves ADCC‐Mediated Antibody Therapy in Colorectal Cancer

Abstract The epidermal growth factor receptor (EGFR) is a validated therapeutic target for RAS/RAF wild‐type colorectal cancer (CRC). However, monoclonal antibody‐based anti‐EGFR therapies such as cetuximab have limited effectiveness. Herein, it is identified that EGFR internalization is associated...

Full description

Saved in:
Bibliographic Details
Main Authors: Chong Wu, Xiaoting Liu, Rong Liu, Shiyao Song, Zi‐Fan Zheng, Yilin Zeng, Yong Mei, Jing‐Yang Zhang, Qijia Duan, Run Lin, Jin‐Zhi Du, Weiling He
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Advanced Science
Subjects:
Online Access:https://doi.org/10.1002/advs.202407239
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850123822147043328
author Chong Wu
Xiaoting Liu
Rong Liu
Shiyao Song
Zi‐Fan Zheng
Yilin Zeng
Yong Mei
Jing‐Yang Zhang
Qijia Duan
Run Lin
Jin‐Zhi Du
Weiling He
author_facet Chong Wu
Xiaoting Liu
Rong Liu
Shiyao Song
Zi‐Fan Zheng
Yilin Zeng
Yong Mei
Jing‐Yang Zhang
Qijia Duan
Run Lin
Jin‐Zhi Du
Weiling He
author_sort Chong Wu
collection DOAJ
description Abstract The epidermal growth factor receptor (EGFR) is a validated therapeutic target for RAS/RAF wild‐type colorectal cancer (CRC). However, monoclonal antibody‐based anti‐EGFR therapies such as cetuximab have limited effectiveness. Herein, it is identified that EGFR internalization is associated with poor treatment response and prognosis in patients with CRC, based on a retrospective analysis of patients treated with cetuximab. It is further demonstrated that the endocytosis inhibitor prochlorperazine (PCZ) can move EGFR, which is hidden inside the cell, to the cell surface to improve therapeutic antibody binding. Thus, a thermosensitive hydrogel co‐loaded with cetuximab and PCZ (Gel@Cmab/PCZ) is constructed for sustained inhibition of endocytosis and effective cetuximab delivery. Peritumoral injection of Gel@Cmab/PCZ shows strong antitumor efficacy in subcutaneous and orthotopic CRC tumor models and completely abrogated liver metastasis when combined with chemotherapy. In a humanized patient‐derived xenograft model, a single injection of Gel@Cmab/PCZ with one‐third of the conventional cetuximab dose achieved 91% tumor growth inhibition, which promoted NK cell infiltration into tumor tissues and their antibody‐dependent cell‐mediated cytotoxicity effect. This study represents a novel strategy to boost the monoclonal antibody‐mediated anti‐tumor response in CRC.
format Article
id doaj-art-1d5dcc9f55014bce99dea0df70149aad
institution OA Journals
issn 2198-3844
language English
publishDate 2025-01-01
publisher Wiley
record_format Article
series Advanced Science
spelling doaj-art-1d5dcc9f55014bce99dea0df70149aad2025-08-20T02:34:31ZengWileyAdvanced Science2198-38442025-01-01122n/an/a10.1002/advs.202407239Sustained Endocytosis Inhibition via Locally‐Injected Drug‐Eluting Hydrogel Improves ADCC‐Mediated Antibody Therapy in Colorectal CancerChong Wu0Xiaoting Liu1Rong Liu2Shiyao Song3Zi‐Fan Zheng4Yilin Zeng5Yong Mei6Jing‐Yang Zhang7Qijia Duan8Run Lin9Jin‐Zhi Du10Weiling He11Department of Gastrointestinal Surgery The First Affiliated Hospital Sun Yat‐sen University Guangzhou Guangdong 510080 ChinaDepartment of Gastrointestinal Surgery The First Affiliated Hospital Sun Yat‐sen University Guangzhou Guangdong 510080 ChinaSchool of Medicine South China University of Technology Guangzhou Guangdong 510006 ChinaDepartment of Pediatrics, The First Affiliated Hospital Sun Yat‐sen University Guangzhou Guangdong 510080 ChinaDepartment of Gastrointestinal Surgery The First Affiliated Hospital Sun Yat‐sen University Guangzhou Guangdong 510080 ChinaDepartment of Radiology, The First Affiliated Hospital Sun Yat‐sen University Guangzhou Guangdong 510080 ChinaDepartment of Gastrointestinal Surgery The First Affiliated Hospital Sun Yat‐sen University Guangzhou Guangdong 510080 ChinaSchool of Biomedical Sciences and Engineering, Guangzhou International Campus South China University of Technology Guangzhou Guangdong 511442 ChinaSchool of Medicine South China University of Technology Guangzhou Guangdong 510006 ChinaDepartment of Radiology, The First Affiliated Hospital Sun Yat‐sen University Guangzhou Guangdong 510080 ChinaSchool of Medicine South China University of Technology Guangzhou Guangdong 510006 ChinaDepartment of Gastrointestinal Surgery The First Affiliated Hospital Sun Yat‐sen University Guangzhou Guangdong 510080 ChinaAbstract The epidermal growth factor receptor (EGFR) is a validated therapeutic target for RAS/RAF wild‐type colorectal cancer (CRC). However, monoclonal antibody‐based anti‐EGFR therapies such as cetuximab have limited effectiveness. Herein, it is identified that EGFR internalization is associated with poor treatment response and prognosis in patients with CRC, based on a retrospective analysis of patients treated with cetuximab. It is further demonstrated that the endocytosis inhibitor prochlorperazine (PCZ) can move EGFR, which is hidden inside the cell, to the cell surface to improve therapeutic antibody binding. Thus, a thermosensitive hydrogel co‐loaded with cetuximab and PCZ (Gel@Cmab/PCZ) is constructed for sustained inhibition of endocytosis and effective cetuximab delivery. Peritumoral injection of Gel@Cmab/PCZ shows strong antitumor efficacy in subcutaneous and orthotopic CRC tumor models and completely abrogated liver metastasis when combined with chemotherapy. In a humanized patient‐derived xenograft model, a single injection of Gel@Cmab/PCZ with one‐third of the conventional cetuximab dose achieved 91% tumor growth inhibition, which promoted NK cell infiltration into tumor tissues and their antibody‐dependent cell‐mediated cytotoxicity effect. This study represents a novel strategy to boost the monoclonal antibody‐mediated anti‐tumor response in CRC.https://doi.org/10.1002/advs.202407239antibody‐dependent cell‐mediated cytotoxicitycolorectal cancerendocytosis inhibitionepidermal growth factor receptorhydrogeltargeted therapy
spellingShingle Chong Wu
Xiaoting Liu
Rong Liu
Shiyao Song
Zi‐Fan Zheng
Yilin Zeng
Yong Mei
Jing‐Yang Zhang
Qijia Duan
Run Lin
Jin‐Zhi Du
Weiling He
Sustained Endocytosis Inhibition via Locally‐Injected Drug‐Eluting Hydrogel Improves ADCC‐Mediated Antibody Therapy in Colorectal Cancer
Advanced Science
antibody‐dependent cell‐mediated cytotoxicity
colorectal cancer
endocytosis inhibition
epidermal growth factor receptor
hydrogel
targeted therapy
title Sustained Endocytosis Inhibition via Locally‐Injected Drug‐Eluting Hydrogel Improves ADCC‐Mediated Antibody Therapy in Colorectal Cancer
title_full Sustained Endocytosis Inhibition via Locally‐Injected Drug‐Eluting Hydrogel Improves ADCC‐Mediated Antibody Therapy in Colorectal Cancer
title_fullStr Sustained Endocytosis Inhibition via Locally‐Injected Drug‐Eluting Hydrogel Improves ADCC‐Mediated Antibody Therapy in Colorectal Cancer
title_full_unstemmed Sustained Endocytosis Inhibition via Locally‐Injected Drug‐Eluting Hydrogel Improves ADCC‐Mediated Antibody Therapy in Colorectal Cancer
title_short Sustained Endocytosis Inhibition via Locally‐Injected Drug‐Eluting Hydrogel Improves ADCC‐Mediated Antibody Therapy in Colorectal Cancer
title_sort sustained endocytosis inhibition via locally injected drug eluting hydrogel improves adcc mediated antibody therapy in colorectal cancer
topic antibody‐dependent cell‐mediated cytotoxicity
colorectal cancer
endocytosis inhibition
epidermal growth factor receptor
hydrogel
targeted therapy
url https://doi.org/10.1002/advs.202407239
work_keys_str_mv AT chongwu sustainedendocytosisinhibitionvialocallyinjecteddrugelutinghydrogelimprovesadccmediatedantibodytherapyincolorectalcancer
AT xiaotingliu sustainedendocytosisinhibitionvialocallyinjecteddrugelutinghydrogelimprovesadccmediatedantibodytherapyincolorectalcancer
AT rongliu sustainedendocytosisinhibitionvialocallyinjecteddrugelutinghydrogelimprovesadccmediatedantibodytherapyincolorectalcancer
AT shiyaosong sustainedendocytosisinhibitionvialocallyinjecteddrugelutinghydrogelimprovesadccmediatedantibodytherapyincolorectalcancer
AT zifanzheng sustainedendocytosisinhibitionvialocallyinjecteddrugelutinghydrogelimprovesadccmediatedantibodytherapyincolorectalcancer
AT yilinzeng sustainedendocytosisinhibitionvialocallyinjecteddrugelutinghydrogelimprovesadccmediatedantibodytherapyincolorectalcancer
AT yongmei sustainedendocytosisinhibitionvialocallyinjecteddrugelutinghydrogelimprovesadccmediatedantibodytherapyincolorectalcancer
AT jingyangzhang sustainedendocytosisinhibitionvialocallyinjecteddrugelutinghydrogelimprovesadccmediatedantibodytherapyincolorectalcancer
AT qijiaduan sustainedendocytosisinhibitionvialocallyinjecteddrugelutinghydrogelimprovesadccmediatedantibodytherapyincolorectalcancer
AT runlin sustainedendocytosisinhibitionvialocallyinjecteddrugelutinghydrogelimprovesadccmediatedantibodytherapyincolorectalcancer
AT jinzhidu sustainedendocytosisinhibitionvialocallyinjecteddrugelutinghydrogelimprovesadccmediatedantibodytherapyincolorectalcancer
AT weilinghe sustainedendocytosisinhibitionvialocallyinjecteddrugelutinghydrogelimprovesadccmediatedantibodytherapyincolorectalcancer